Skip to main content
2025 CRT Conference Main banner
Back

Peter Libby, MD

Cardiovascular Specialist
Brigham and Women's Hospital
Boston, Massachusetts, United States

Peter Libby, MD, is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. He served as Chief of Cardiovascular Medicine at BWH from 1998-2014. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translate his basic laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials.
An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals He is an Editor of Braunwald’s Heart Disease. He has held numerous visiting professorships and delivered more than 150 major named or keynote lectures throughout the world.

Disclosure(s): Amgen: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Baim Institute: Consultant (Ongoing); Beren Therapeutics: Consultant (Ongoing); Caristo Diagnostics: Scientific Advisory Board (Ongoing); CSL Behring: Scientific Advisory Board (Ongoing); Elucid Bioimaging: Scientific Advisory Board (Ongoing); Esperion Therapeutics: Consultant (Ongoing); Genentech: Consultant (Ongoing), Grant/Research Support (Ongoing); Kancera: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Kowa Pharmaceuticals: Consultant (Ongoing), Scientific Advisory Board (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Scientific Advisory Board (Ongoing); Novo Nordisk: Consultant (Ongoing), Grant/Research Support (Ongoing); Olatec Therapeutics: Scientific Advisory Board (Ongoing); PlaqueTec Ltd: Scientific Advisory Board (Ongoing); Polygon Therapeutics: Scientific Advisory Board (Ongoing); Sanofi-Regeneron: Consultant (Ongoing); Soley Thereapeutics: Financial Interest (Ongoing); TenSixteen Bio: Financial Interest (Ongoing); XBiotech, Inc.: Board of Directors (Ongoing), Employee (Ongoing)

Presentation(s):